Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas
- PMID: 16307652
- DOI: 10.1111/j.1365-2133.2005.06883.x
Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas
Abstract
Background: Melanomas are heterogeneous tumours, and differentiation from other melanocytic lesions may cause problems. It may be possible that the distribution and/or colocalization pattern of different markers in the lesions can enable a more accurate diagnosis of melanocytic tumours.
Objectives: To test this hypothesis, melanocytic naevi, primary melanomas and metastases were investigated.
Methods: The distribution and colocalization of markers for proliferation, invasion, angiogenesis and motility of the tumour cells were investigated using antibodies directed against actin, cathepsin B (CatB), transforming growth factor-beta, vascular endothelial growth factor (VEGF), proliferating cell nuclear antigen/Ki-67 and basic fibroblast growth factor (FGF-2). In addition, melanoma markers (HMB-45 and Melan-A) and proteins unrelated to melanoma progression [epidermal growth factor (EGF) and cathepsin H] were investigated.
Results: Malignant melanomas tended to express more markers of malignancy compared with melanocytic naevi, and the differences were statistically significant for EGF and actin immunoreactivity: melanocytic naevi displayed clear EGF labelling more often (60% vs. 5%) and melanomas showed more intense actin labelling (70% vs. 0%). HMB-45+ cells to a large extent also stained with antibodies to CatB but not to EGF or actin; EGF-, FGF-2- and VEGF-immunoreactive cells were predominantly HMB-45-. Similar combinations were observed in melanocytic naevi and in melanomas.
Conclusions: Labelling with EGF may improve the differential diagnosis of melanocytic neoplasias. However, we did not detect a clear-cut increase of markers of malignancy in melanoma. Cells expressing multiple malignancy markers were also found in some melanocytic naevi; this may confirm the dormant potential of melanocytic naevi for melanoma development.
Similar articles
-
Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.J Pathol. 2001 Jun;194(2):194-200. doi: 10.1002/1096-9896(200106)194:2<194::AID-PATH851>3.0.CO;2-S. J Pathol. 2001. PMID: 11400148
-
Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in human malignant melanoma and their relation to angiogenesis.Clin Exp Dermatol. 2006 May;31(3):413-8. doi: 10.1111/j.1365-2230.2006.02123.x. Clin Exp Dermatol. 2006. PMID: 16681591
-
Micro-anatomy related antigen expression in melanocytic lesions.J Pathol. 2000 Apr;190(5):572-8. doi: 10.1002/(SICI)1096-9896(200004)190:5<572::AID-PATH570>3.0.CO;2-9. J Pathol. 2000. PMID: 10727983
-
The approach to the patient with a difficult melanocytic lesion.Pathology. 2004 Oct;36(5):428-34. doi: 10.1080/00313020412331283905. Pathology. 2004. PMID: 15370112 Review.
-
[Immuno-diagnosis of malignant melanoma].Magy Onkol. 2003;47(1):45-50. Epub 2003 Apr 18. Magy Onkol. 2003. PMID: 12704454 Review. Hungarian.
Cited by
-
Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity.Cancer. 2012 Dec 1;118(23):5848-56. doi: 10.1002/cncr.27540. Epub 2012 May 17. Cancer. 2012. PMID: 22605570 Free PMC article. Clinical Trial.
-
Association between cathepsins and skin cancers: A bidirectional two-sample Mendelian randomization study.Skin Res Technol. 2024 Aug;30(8):e13905. doi: 10.1111/srt.13905. Skin Res Technol. 2024. PMID: 39138831 Free PMC article.
-
The role of VEGF in melanoma progression.J Res Med Sci. 2012 Jun;17(6):534-9. J Res Med Sci. 2012. PMID: 23626629 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical